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Aljobaily, Nouf. Cannabigerol attenuate methionine/choline deficient diet- induced nonalcoholic 
steatohepatitis symptoms in C57BL/6 male mice via modulating the expression of 
cannabinoid receptors. Unpublished Master of Science thesis, University of Northern 
Colorado, 2021. 
Non-Alcoholic Steatohepatitis (NASH) is the advanced and more aggressive form of 
Non-Alcoholic Fatty Liver Disease (NAFLD). NASH is associated with severe hepatic fibrosis 
and inflammation. Methionine/choline deficient (MCD) high fat diet is known to induce NASH 
in a short period of time without showing signs of metabolic syndrome. Cannabigerol (CBG) is a 
plant-derived, non-psychotropic cannabinoid that has a potential anti-inflammatory effect. Other 
hemp extracts reduce the progression of NAFLD to NASH, whereas the impact of CBG on 
NASH is still unknown. Therefore, these studies aim to 1. Evaluate the therapeutic potential of 
CBG on reducing hepatic steatosis and fibrosis. 2. Evaluate the anti-inflammatory effect of CBG 
in MCD-induced NASH C57BL/6 male mice. 3. Evaluate how CBG interacts with CB1 and CB2 
receptors. Liver tissues were harvested from C57BL/6 mice (n = 36) fed with MCD or high fat 
control (CTR) diets for three weeks then the mice were divided into three sub-groups and 
injected with a vehicle solution, low or high dose of CBG for two additional weeks. Body 
weight, liver-to-body weight ratio, serum chemistry and H&E staining were also measured to 
evaluate the overall health of mice, liver function and morphology. Moreover, various 
histological tests were performed to evaluate collagen deposition, inflammation, and fat 
deposition. In addition, the expression of cannabinoid receptors was evaluated using 
immunofluorescence staining. 




It is concluded that MCD diet caused a significant body weight loss in mice (55), while CBG 
administration showed a trend towards recovery of their body weight, liver-to-body weight ratio, 
as well as ALT levels in MCD diet group. Further, inflammation decreased with low CBG 
treatment but increased when treated with a high dose of CBG in both the CTR and MCD 
groups. Similarly, the expression of cannabinoid (CB) receptors 1 and 2 showed increased 
expression with high dose CBG, but alleviated expression with low CBG dose intervention in 
MCD group. Collectively, low dose of CBG can reduce fibrosis and inflammation in MCD-
induced NASH. CBG is gaining traction as a commercially available supplement with a variety 
of health-related claims. These results will provide rigorously controlled pre-clinical data to 
guide future intervention studies in humans addressing the potential uses of CBG for 
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Overview of Non-Alcoholic Fatty Liver Disease  
Epidemiology, Diagnosis and Treatments 
A person could develop a fatty liver by either excessive alcoholic consumption or 
excessive calorie consumption as part of an unhealthy diet (1). Non-Alcoholic Fatty Liver 
Disease (NAFLD) is one of the most common forms of chronic liver diseases (2), characterized 
by accumulation of more than 5% of fat in the liver (2) independent of alcoholic consumption 
(1). NAFLD is associated with obesity, type-2 diabetes, and metabolic syndrome (3). Globally, 
25% of the world population and 24.13% of the United States population is estimated to have 
NAFLD (4). Further, it is projected that 100 million individuals in the United Stated will develop 
NAFLD by 2030 (4), as it is expected to increase by 33.5% in the next ten years (2). It is also 
projected that NAFLD incidence will increase in North America as obesity continues to rise (5).  
Currently, there are limited ways to diagnose NAFLD, which include serum chemistry 
analysis and/or liver biopsy. Serum chemistry analysis includes measuring alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) levels (6). While both ALT and 
AST enzymes are present in various organs, they are primary found in the liver and the kidney 
and are responsible for the transfer amino acids. Change in serum ALT and/or AST levels could 
be used as an indicator for the presence of liver fibrosis. Hepatic steatosis is defined as the 
accumulation of fat in the liver cells (hepatocytes). NAFLD starts as simple steatosis but can 
progress to more severe stages (7). The second stage of NAFLD, called Non-Alcoholic 




(fibrosis) (8). NASH could further progress to liver cirrhosis and/or hepatocellular carcinoma. At 
that stage, the liver starts to fail, and patients require a liver transplant (9). Hence, a change in 
lifestyle, including continuous exercise and eating a healthy diet, is the only current way to 
reverse NAFLD, enabling a return to a healthy liver with no or less than 5% fat accumulation, 
which prevent the development of NASH. More specifically, it has been suggested that losing 
around 3% of total body weight might enhance the reduction of hepatic steatosis (8).   
Non-Alcoholic Steatohepatitis Epidemiology,  
Diagnosis and Proposed Treatments 
NASH is the more aggressive stage of NAFLD associated with hepatic inflammation and 
hepatic fibrosis (8). Fibrosis is defined as thickening of the connective tissues as a result of 
continues scarring. In NASH, the scaring is developed as a result to the accumulation of fat in 
the liver. Thus, it is estimated that 20-25% of NAFLD cases in the United States are at the 
NASH stage, of which 3-4% of those cases are estimated to have cirrhosis (10). Further, between 
2007 and 2016, 2% of the US deaths were NAFLD/NASH-related (48). Like NAFLD, NASH is 
clinically diagnosed via either liver biopsy and/or serum chemistry analyses. However, unlike 
NAFLD, NASH is not known to be reservable (11). Yet, it is suggested that a 10% reduction in 
total body weight could help in reducing inflammation associated with NASH (8, 12). However, 
the change in lifestyle was found to be hard to maintain in NASH patients. Currently, there are 
no FDA-approved treatments for NASH, which highlights the importance of research on seeking 
effective treatments for NASH. Some NASH patients have required a liver transplant due to the 
development of liver cirrhosis and its related complications (9, 48, 49). However, this is not an 
adequate way to treat the disease as not all NASH patients have immediate access to a transplant 
liver. In addition, there are serious complications associated with the liver transplant such as bile 




Liver transplant rejection is another major complication, which is a response of the immune 
system. Although there are lower transplant rejection incidences due to the improve in immune 
suppressive therapies, there are still a significant clinical liver transplant rejection rate (54).  
Various treatments have been suggested or are currently in clinical trials to treat or slow down 
the progression of the disease. Peroxisome proliferator-activator receptors (PPARs) have been 
investigated as a target for NASH. While PPAR-α agonist did not show an affect in reducing 
NASH, PPAR-γ agonist showed an alleviation in NASH through histological data but not in 
alanine transaminase (ALT) levels or body weights. However, PPAR-α/γ combination showed 
alleviation in serum ALT levels, insulin resistance and body weight (8, 13, 14). Further, Tumor 
Necrosis Factor alpha (TNF-α) is a NASH biomarker associated with hepatic inflammation. It is 
known that endoplasmic reticulum (ER) stress mediates TNF-α activation in response to NASH 
as well as hepatocyte injury and cellular apoptosis; thus, it has been proposed that a blockade of 
TNF-α using emricasan, a drug designed to inhibit caspase activity,  reduces the morphological 
effect in NASH patients. This study ended in phase IIb clinical trials and emricasan did not 
improve NASH histology or liver fibrosis and liver ballooning (8, 15-17). Further, supplements 
such as omega-3 (51) and vitamin E have been used in NASH patients due to its antioxidant 
characteristic. It has been shown to decrease ER stress as well as inflammation (18), which is 
thought to be the start point to initiate hepatic fibrosis and inflammation. 
Cannabidiol in Liver Diseases 
Cannabinoids are commercially available and are being used by the general population in 
various forms for medical purposes due to their widely recognized anti-inflammatory effects. 
However, there are many unknowns about the side effects of cannabis, and it is still controversial 




CBD could be used to attenuate diseases such as anxiety, bowel disease (28) and NAFLD (19). 
When C57BL/6 mice were administered either 5 or 10 mg/kg/day CBD treatment, they showed a 
reduction in liver steatosis as well as liver inflammation. This treatment did not appear to have 
any impact on the brain (19). Even after these findings, the impact of CBD on the liver is still 
debatable due to the risk of drug-to drug interaction, as well as the associated hepatocellular 
injuries and hepatic abnormalities (52). Another complication that was observed in human liver 
was elevated serum chemistry function including, but not limited to, AST, ALT, and γ-glutamyl 
transferase (GGT) levels (52, 53). Thus, further study of the potential effect of CBD on the liver 
as well as the potential application of other cannabinoids as anti-inflammatory alternatives to 
CBD in liver treatment is needed. Despite the popularity of various forms of cannabis, there is 
still little known about their molecular mechanisms and effect on the liver. In addition, 
cannabidiol (CBD) is a form of cannabis derivative with anti-inflammatory characteristics that 
have been found to reduce liver steatosis, inflammation, and oxidative stress (19). Nevertheless, 
the therapeutic effect of cannabis is still not fully understood. A recent study by Abulseoud et. 
al. suggested that the therapeutic effect of cannabis is dose-dependent, suggesting that low 
dosages could be helpful while high dosages could have a harmful impact (20).  
Cannabinoid Receptors and their Role in Liver Diseases 
Endocannabinoid (EC) signaling has been widely investigated in the central nervous 
system (CNS) as it has been shown to regulate the appetite. Additionally, cannabinoid (CB) 
receptors are G-protein coupled receptors that have been found to be abundant in various 
mammalian tissues including the liver (21, 22). Currently, there are two known CB receptors in 
the liver CB1 and CB2. CB1 has been shown to be involved in hepatic steatosis, fibrosis and 




receptors have been used as a therapeutic target in various liver metabolic related diseases such 
as NAFLD, NASH and hepatocellular carcinoma (24-26). In fact, the CB1 receptor is the 
receptor predominantly expressed in the CNS to regulate appetite, mood and pain, whereas CB2 
is found to play a role in the immune system response and in the gastrointestinal tract. Further, a 
study suggested that CB receptors play a role in the development and the metabolism of the liver 
(27).   
Recent Research Using Cannabigerol 
CBD is derived from the precursor Cannabigerol (CBG), C21H32O2, which is a form of 
cannabinoid found in the plant cannabis sativa that does not have the psychotropic effect that 
tetrahydrocannabinol (THC) has (29). Due to the novelty of CBG, few studies investigated the 
therapeutic mechanism of CBG (28, 30). It was shown that CBG has an anti-inflammatory, anti-
proliferative and anti-bacterial effect on a variety of diseases and disorders (28) such as CNS 
diseases (29), breast cancer (31), antibiotic resistance (32, 33) and anti-glaucoma (28). 
Nevertheless, the impact of CBG on the liver has not yet been investigated. Therefore, this study 
aims to evaluate the role of CBG in improving liver function in diet-induced NASH using a 
mouse model. 
Cannabigerol as Potential Treatment for  
Non-Alcoholic Steatohepatitis 
This study will advance the medical and pharmaceutical field in various ways. CBG 
could target CB1 receptor which is expressed in the liver and could be a potential target when 
considering drug synthesis (29). Further, NASH reversibility is controversial; some studies 
suggest that NASH cannot be reversed back to NAFLD whereas other studies suggested that it 
can. Therefore, this study aims to investigate whether CBG could reverse NASH back to 




Methionine/Choline-Deficient Diet to Induce  
Non-Alcoholic Steatohepatitis in Rodents 
Methionine/Choline-deficient (MCD) diet is a widely used high fat diet (Table 1) 
containing 455.294 g/kg of sucrose, 200 g/kg of corn starch, 30 g/kg of cellulose, and 100 g/kg 
of corn oil. It is known to induce NASH by inhibiting the synthesis of very-low-density 
lipoprotein (VLDL) as well as stearoyl-CoA desaturase-1 (SCD1), leading to failure in exporting 
lipid from the liver (35). The excessiveness of lipid accumulation in the liver decreases the 
regeneration of hepatocytes which leads to hepatic fibrosis (36), potentially triggered by 
oxidative stress. Although MCD diet does not fully replicate the human NASH symptoms 
because it fails to show metabolic syndrome, insulin resistance and body weight gain; it 
replicates other NASH symptoms such as hepatic steatosis, inflammation, ER stress, cellular 
apoptosis and fibrosis over a short period of time (37). It is important to keep this in mind while 
interpreting the data. In this study we are specifically interested in the main pathologic features 
of NASH which are hepatic steatosis, fibrosis, and inflammation.  
Goal and Aims 
The current understanding of NASH suggests that it is not reversible while NAFLD is 
known to be a reversible condition (11).  A schematic representation is shown in Figure 1 
summarizing the overall goal of this study. It was hypothesized that CBG would be used as a 
therapeutic agent to alleviate NASH symptoms as it has been suggested to have an anti-
inflammatory effect (28) (Figure 1) and thus might help reducing the liver damage. Initially, 
body weight, liver to body weight ratio and ALT levels were obtained to assess the general 
health of the mice. Therefore, this study is intended to evaluate the efficacy of CBG in 





A1  Evaluate the effect of different dose of CBG on reducing hepatic steatosis and 
hepatic fibrosis in MCD-induced NASH C57BL/6 male mice. 
 
Our working hypothesis was that CBG will not impact steatosis as other cannabinoids 
have shown to increase appetite. However, we expected that CBG would decrease hepatic 
fibrosis. In order to accomplish this aim, steatosis is measured using histological and 
immunohistochemical assays, and qRT-PCR; while fibrosis is measured using Pico-Sirius Red 
staining, immunofluorescence staining and qRT-PCR. 
A 2   Evaluate the effect of different dose of CBG on alleviating inflammation in 
C57BL/6 mice that were induced with NASH by a MCD diet.  
 
Our working hypothesis was that low CBG concentration would reduce inflammation 
while high CBG concentration would cause enhanced inflammation. Immunofluorescence 
staining was utilized to assess inflammation using NASH-inflammation related biomarkers. 
While gene expression at the mRNA level was evaluated using qRT-PCR.  
A 3  Investigate the change in gene expression of the two known forms of CB 
receptors in liver tissues.  
 
The working hypothesis was that the gene expression of the CB1 receptor would increase 
in groups receiving CBG. CB1 is related to controlling appetite, while CBG might be a precursor 
to trigger the expression of the CB1 receptor. In the liver, CB2 receptor was predicted to show 
similar trends to the inflammatory response where the expression decreased with the increase of 




against CB1 and CB2 receptors was used to evaluate the expression of the receptors with 
intervention of difference CBG doses.    







METHODOLOGY AND MATERIALS 
Diet, Reagents, and Primers 
Control diet (CTR) and Methionine/Choline-Deficient diet (MCD) (table 1) were 
purchased from Envigo (Denver, CO, USA), while all other reagents and primers were purchased 
from Thermo Fisher Scientific (Denver, CO, USA), VWR (Radnor, PA, USA), Biolegend (San 
Diego, CA, USA), and Invertogen (Fredrick, MD, USA) unless otherwise indicated. CBG 
treatment was generously provided by Mile High Labs. (Broomfield, CO, USA).  
Animal, Diets and Cannabigerol Treatments 
All proposed procedures have been approved by the Institutional Animal Care and Use 
Committee at the University of Northern Colorado (protocol no. 1910CE-YH-M-22). Male 
C57BL/6 mice have been used in this study due to the fact that they show NASH symptoms 
faster than female C57BL/6 female mice (56). Male C57BL/6 mice were obtained from the 
University of Northern Colorado Animal Facility (n=36) and were randomly assigned into either 
the control group (TD.94149, n=18) or the MCD diet group (TD.90262, n= 18) and were fed the 
assigned diet for 3 weeks as the MCD diet has the ability of inducing NASH by the end of the 
third week. Then, they were randomized in three-subgroups and intraperitoneally (I.P.) injected 
with a vehicle, a low dose (2.46 mg/kg/day) (L. CBG) or a high dose (24.6 mg/kg/day) (H. CBG) 
of CBG for three times a week for two additional weeks during the course of the diet. All 
animals were housed in the animal facility at the University of Northern Colorado for 5 weeks 
and euthanized on the last day of the study using the recommended dose of EUTHASOL® and 




Institutional Animal Care and Use Committee and the Collaborative Institutional Training 
Initiative guidelines.  
To prepare high dose CBG treatment, 6.642 mg of anhydrous CBG was dissolved in 10µl 
of tween-80 and then added in 37.5 µl of Dimethyl sulfoxide (DMSO). Upon injection, 
Phosphate-buffered saline (PBS) was freshly mixed with the reagents described above to avoid 
cross-contamination. The low dose of CBG was 10x less concentrated than the high dose CBG, 
diluted in PBS (1:10 dilution). The vehicle solution was the same solution for dissolve the high 
dose CBG but without the CBG.  
Liver Harvest and Blood Collection 
Upon sacrifice, roughly 500µL of peripheral blood was collected and centrifuged at a 
speed of 123 xg for 5 minutes to isolate the serum. Isolated serum was snap frozen in liquid 
nitrogen and stored in -80ᵒ C for further analyses. In order to assess liver health, serum samples 
were sent to the Veterinary Teaching Hospital Diagnostic Laboratories at Colorado State 
University to analyze the levels of ALT. Post sacrifice, liver tissues were harvested and weighed. 
Then, they were either embedded in an Optimal Cutting Temperature (OCT) medium and snap 
frozen in liquid nitrogen or directly snap frozen in liquid nitrogen. All samples were stored in -
80ᵒ C until used except of tissues used for RNA-related analyses which were stored in 4ᵒ C.  
Histology 
Hematoxylin and  
Eosin Staining 
To evaluate overall liver health, Hematoxylin and Eosin staining was performed. 8µm 
frozen liver sections were fixed in 10% Neutral buffered formalin (NBF) for 10 minutes 
followed by a wash in 95% ethanol and 2-3 changes of tap water rinse. Tissues were then stained 




95% ethanol followed by eosin stain for 10 seconds. After that, they were dehydrated in 2 
changes of 95% ethanol followed by 3 changes of 100% ethanol. Finally, tissues were washed in 
2 changes of xylene and mounted with a mounting medium. All images were taken at 20x 
magnification.   
Oil-Red-O Staining 
Lipid accumulation was evaluated using Oil-Red-O staining. 8µm frozen liver sections 
were fixed in 10% Neutral buffered formalin (NBF) for 10 minutes then immediately washed in 
3 changes of distilled water. Tissues were then placed in 100% propylene glycol for 5 minutes 
followed by pre-heated Oil-Red-O staining for 8 minutes. After that, they were placed in 85% 
propylene glycol for 5 minutes and rinsed in 2 changes of distilled water. Further, tissues were 
counterstained with Hematoxylin for 40 seconds and washed afterward in running tap water for 3 
minutes. Last, tissues were mounted in aqueous mounting media. All images were taken at 20x 
magnification.   
Pico-Sirius Red Staining 
Liver fibrosis was assessed using Pico-Sirius Red staining. 8µm frozen liver sections 
were fixed in 10% Neutral buffered formalin (NBF) for 10 minutes followed by xylene for ten 
minutes. Then they were rehydrated in 100%, 90% then 70% ethanol. Then, the nucleus was 
stained with hematoxylin for 40 seconds followed by a rinse in tap water for 10 minutes. Then, 
tissues were stained for collagen deposition using Pico-Sirius Red stain for 1 hour followed by 2 
washes in 0.5% acidified water and dehydrated in 70%, 90% and 100% ethanol. Finally, tissues 







Total RNA was extracted using Pure Link™ RNA Mini Kit obtained from Invitrogen and 
converted into cDNA using High-Capacity cDNA Reverse Transcription Kit obtained from 
Applied Biosystems™, according to manufactures’ recommendations. qRT-PCR was performed 
to analyze the mRNA expression of ATGL (triglyceride), CD36 (fatty acid transferase, 
steatosis), α-SMA (alpha smooth muscle actin, fibrosis), IL-6 (interleukin 6, inflammation), 
TGF-β1 (transforming growth factor, inflammation), CB1 (cannabinoid receptor 1) and CB2 
(cannabinoid receptor 2) and normalized to GAPDH (Table 2- primer sequences). Six biological 
replicates were used to measure relative gene expression at the transcriptional level unless 
otherwise indicated. All genes expressions were normalized to GAPDH.   
Immunofluorescence Staining 
8µm frozen liver sections were fixed in 10% NBF for 10 minutes then washed with 1X 
PBS. Sections were then blocked for 20 minutes with 10% normal goat serum diluted in 1X PBS, 
followed by a rinse in 1X PBS. Thereafter, sections were incubated in primary antibody 
overnight in a 4ᵒ C incubator except for the Bodipy dye which was incubated for 30 minutes. The 
next day, specimens were washed with 1X PBS and stained with the secondary antibody for 45 
minutes in the dark at room temperature. Finally, tissues were mounted with DAPI mounting 
medium and stored in -20ᵒ C until analyzed with a Zeiss 700 confocal microscope. All images 
were taken at 20x magnification and quantified using Fiji ImageJ software (Table 3).  
Statistical Procedures 
All data were analyzed using GraphPad Prism 9 software and reported as mean ± SEM 
(Standard Error Mean). The Shapiro-Wilk test was performed to test the normality assumption 




that, a one-way analysis of variance (ANOVA) was performed to test significant difference 
between group means for each experiment in this study. After performing ANOVA tests, 
Tukey’s post hoc tests were performed comparing every pair of groups to indicate which group 
is causing the significance in the ANOVA tests, when significance is detected. Finally, Pearson’s 
correlation was performed to test if a significant relationship exists between the liver weight and 
body weight of mice. For all tests used, a p-value ≤ 0.05 was considered significant. 
Table 1. MCD diet and MCD control diet components. 
Formula  CTR MCD  
L-Amino acids (g/kg) 156.4 156.4 
L-Methionine (g/kg) 8.2 0.0 
Choline chloride (g/kg) 350 g/kg* 0.0 
Sucrose (g/kg) 443.597 455.294 
Corn starch (g/kg) 198.783 200.0 
Cellulose (g/kg) 30.0 30.0 
Corn oil (g/kg) 100.0 100.0 
Salt mix (g/kg) 35.5 35.0 
Vitamin mix (g/kg) 10.0 5.0 
* information was taken from PMID: 26267291.  
 
Table 2. Primer sequences for qRT PCR. 
Gene Forward Reverse 
AGTL CAACGCCACTCACATCTACGG GGACACCTCAATAATGTTGGCA 
CD36 AATTAGTAGAACCGGGCCAC CCAACTCCCAGGTACAATCA 
α-SMA ACTGGGACGACATGGAAAAG AGAGGCATAGAGGGACAGCA 
IL-6 CATCTGTGAGTGGCGTCCGA AACGCTTCGTTGTGGCTGGA 
TGF-β1 GAGCCCGAAGCGGACTACTA CACTGCTTCCCGAATGTCTGA 
F4/80 TGACAACCAGACGGCTTGTG GCAGGCGAGGAAAAGATAGTGT 
CB1 CCAAGAAAAGATGACGGCAG AGGATGACACATAGCACCAG 
CB2 TCGCTTACATCCTTCAGACAG TCTTCCCTCCCAACTCCTTC 























Table 3. Antibodies and fluorescent dyes dilution and clones 
Antibody/Fluorescent dye COMPANY Dilution Clone 
DNMT1 Invitrogen 1:100 PA3-16556 
a-SMA Invitrogen 1:100 1A4 
CNR1 (CB1) Invitrogen 1:1000 PA1-743 
CNR2 (CB2)  Invitrogen 1:200 PA5-18428 
F4/80 Biolegend 1:100 BM8 
Alexa Fluor 647 Biolegend 1:100 MAR-1 
Alexa Fluor 594 Biolegend 1:100 Poly4053 
FcεRI Biolegend 1:200 MAR-1 
Alexa fluor 488 Biolegend 1:100 Poly4054 
CD45 Biolegend 1:100 OX-1 
a-SMA Biolegend 1:100 1A4 
Bodipy ThermoFisher 1:1000 N/A 
Alexa Fluor® 647 ABCAM 1:200 N/A 
Alexa Fluor® 555 ABCAM 1:200 N/A 
Alexa Fluor® 488 ABCAM 1:200 N/A 









Methionine/Choline-Deficient Diet Changed the Liver  
Morphologies While Low Dose of Cannabigerol  
Seem to Restore the Damaged Liver 
 
Gross morphologies of the subjects’ livers were obtained to further assess the general 
health of the liver as well as whether NASH was induced in the mouse models described above. 
The liver pictures along with the corresponding H&E staining (Figure 2A and 2B) indicate there 
was not a morphological difference between the CTR and CTR L. CBG. However, there was an 
indication of white blood cells infiltration shown as small blue clusters of cells, surrounding the 
blood vesicles in groups fed with MCD diet. Also, an accumulation of lipids shown as white 
circles were observed in CTR H. CBG, MCD, MCD L. CBG and MCD H. CBG (Figure 2B, top 
right and bottom row). There was a significant change among groups in both the liver weight (p< 
0.001, Figure 2C) and the body weight (p< 0.0001, Figure 2D) but not in the liver to body weight 
ratio (p= 0.4535, Figure 2E). This trend led to the investigation of whether there is a correlation 
between the liver weight and the body weight. Interestingly, there was a positive correlation 
between the liver and body weight in the CTR (r= 0.6134), CTR L. CBG (r= 0.8053) and MCD 
L. CBG group (r= 0.4383), meaning, as the liver weight increases, the body weight increases as 
well. On the other hand, the CTR H. CBG (r= -0.1365), MCD (r= -0.5237) and MCD H. CBG 
(r= -0.1059) showed a negative correlation between the liver weight and the body weight, 
indicating that as the liver weight increases, the body weight decreases in those groups. Last, 




biochemical marker for NASH (9). Although there was not a statistical difference detected 
among groups, MCD-treated groups had higher ALT levels (Figure 2G). In general, there was a 
damage associated with the MCD diet and the high dose of CBG in both the CTR and the MCD 
group, but not in the MCD L. CBG. This could be a result of either the high dose of CBG or the 
tween-80 used to dissolve the anhydrous CBG, as it is an oil-based solution which could 
contribute to the lipid accumulation.  
Methionine/Choline-Deficient Diet Increased Steatosis 
Accumulation in Hepatic Tissues as Fatty  
Acid Import Increased 
 
To further assure that steatosis was induced in mice and to assess whether CBG reduced 
the steatosis associated with NASH, Oil-Red-O staining was performed. The data showed that 
there was not an indication of lipid accumulation in all the control groups, whereas there was a 
clear lipid accumulation in all the groups that were fed the MCD diet (lipid is shown in red). 
Within the MCD groups, there was a variation in the size of the lipid droplets. The MCD group 
showed larger lipid droplets when compared to the MCD L. CBG and MCD H. CBG group 
(Figure 3A). Similarly, immunofluorescence staining of neutral lipids (bodipy dye) showed no or 
minimal positivity of lipids in the control groups, while the MCD-fed groups showed a 
significant increase in lipids positivity (p< 0.0001, Figure 3B and 3C). At the transcriptional 
level, CD36 (NASH lipid translocase biomarker) (63, 64) relative gene expression significantly 
changed among groups (p< 0.0001). More specifically, there was a significant increase in CD36 
expression in the MCD group when compared to the CTR group (p< 0.01) indicating that more 
fatty acids were imported into the liver tissue with the MCD diet (Figure 3D). However, the 
CBG treatment did not change the profile of the fatty acid import into the liver tissues. 




related genes, yet ATGL mRNA levels were noted to be the highest in the MCD group (Figure 
3E). Overall, the MCD diet induced NASH by increasing the lipid accumulation observed in the 
liver sections and CD36 gene expression, while CBG treatment did not decrease the lipid 











Figure 2. Evaluation of the overall liver health with the induction of NASH using MCD 
diet and role of CBG in reducing the damage. Macroscopic (A) and Microscopic (B, 20X) 
representation of the liver and after being stained with H&E, showing lipid accumulation and 
white blood cells infiltration with the MCD diet (bottom row). Average liver weight (n=6, C) 
and average body weight (n=6, D), and average liver-to-body weight ratio (E) were measured 
as an initial step in evaluating the overall health of the liver. Correlation between the liver 




Hepatic Fibrosis Decreased with Administration  
of Low Cannabigerol Dose but not with  
High Dose of Cannabigerol 
Along with steatosis, NASH is generally known to be associated with liver fibrosis. In the 
present study, fibrosis was first evaluated by staining for collagen deposition in the liver using 
Sirius Red staining. The data showed that collagen deposition was the highest in the CTR H. 
CBG (p<0.01), MCD (p< 0.01) and MCD H. CBG (p< 0.0001) when compared to the CTR 
group. Further, in was observed that the fibrosis significantly decreased in MCD L. CBG when 
compared to the MCD group (p< 0.05) and MCD H. CBG groups (p< 0.0001) (Figure 4A and 
4B). This observation was consistent with α-SMA immunofluorescence findings, as α-SMA 
expression increased in the MCD group when compared to the CTR group (p<0.0001), while the 
α-SMA expression decreased in both the MCD L. CBG (p< 0.0001) and MCD H. CBG (p< 0.05) 
when compared to the MCD group. Unlike the Sirius Red staining, there was no change between 
the CTR group and CTR H. CBG (p= 0.7879, Figure 4C and 4D). Although no statistical 
significance was detected (p= 0.2347), mRNA expression of α-SMA showed similar patterns to 
the α-SMA immunofluorescence expression. There was an increasing trend in the gene 
expression in both MCD and MCD H. CBG, whereas the gene expression was reduced in the 
MCD L. CBG group (Figure 4E). Taken together, liver fibrosis decreases with a low dose of 






Figure 3. Steatosis was evaluated using histology and qRT-PCR. Microscopic 
representation showing Oil-Red-O staining (A, 20X) and immunofluorescence staining of 
bodipy (green) and DAPI (blue) antibodies (B, 20X). Immunofluorescence staining was 
quantified using ImageJ (C). mRNA expression of CD36 (D) and ATGL (E) were evaluated 






Figure 4. Liver fibrosis was measured by Picro-Sirius Red staining, α-SMA staining and 
mRNA gene expression. Representative pictures and quantification of collagen deposition in 
liver frozen section (A and B, 10X). α-SMA immunofluorescence staining and quantification 
(C and D, 20X) showing α-SMA in red and DAPI (nucleus) in blue (D). Relative gene 




Low Dose of Cannabigerol Decreased Inflammation 
 while High Dose of Cannabigerol Promoted  
Inflammation 
 
NASH is thought to be initiated by the oxidative stress in the liver, which promotes the 
activation of proinflammatory cytokines. Thus, it was vital to investigate the potential anti-
inflammatory effect of CBG in the MCD-induced NASH mouse model used in this study. The 
presence of white blood cells (leukocytes) biomarker CD45 was evaluated as an initial step to 
check the inflammation profile in the liver tissues, and whether CBG aid in reducing the 
inflammation. Figure 5A and 5B showed an increase in the white blood cells biomarker, CD45, 
expression in the CTR H. CBG and MCD groups when compared to the CTR group (p<0.05). 
While in the MCD L. CBG group, the gene expression of CD45 significantly decreased when 
compared to the MCD group (p<0.01), while increasing in the MCD H. CBG group when 
compared to the MCD group (p<0.01) and the MCD L. CBG (p<0.0001). Likewise, the 
expression of the liver macrophages, F4/80, showed similar patterns in immunofluorescence 
staining where there was an increase in expression in the CTR H. CBG group when compared to 
both the CTR and CTR L. CBG groups (p<0.05). Also, there was a decrease in the mRNA and 
protein expression of F4/80 in the MCD L. CBG when compared to the MCD H. CBG group 
(p<0.05); but not when compared to the MCD group (Figure 5C and 5D). Interestingly, there 
was not a change in the gene expression of F4/80 at the transcriptional level between the control 
groups; however, the expression of F4/80 increased in the MCD H. CBG group when compared 
to the MCD (p<0.05) and the MCD L. CBG group (p<0.05, Figure 5E). In addition, there was 
not a change detected among the above-described groups at the transcriptional level of TGFβ1 
and IL-6 (Figure 5F and 5G). Overall, white blood cells infiltration was highest with the 




the white blood cells infiltration in the liver tissues, as well as it reduced the expression of pro-





Figure 5. Immunofluorescence staining and qRT-PCR were utilized to measure 
inflammation in liver tissues. A representative image of liver frozen sections stained for 
white blood cells showing CD45 in red and DAPI in blue (A, 20X), which was quantified 
using ImageJ (B). After, the expression of liver localized macrophages (F4/80) in Frozen liver 
section was evaluated (C) shown in red F4/80, while nucleus is shown in blue. Images of 
F4/80 was also quantified using ImageJ (D). mRNA expression of F4/80 (E) and TGFβ1 (F), 





Cannabinoid Receptors’ Expression is Promoted due to  
Methionine/Choline-Deficient Diet but not with  
the Cannabigerol Administration 
 
Cannabinoid (CB) receptors 1 and 2 have been identified to play a role in the liver 
metabolism and immune system defense, respectively. More specifically, they play a role in 
various liver diseases such as hepatocellular carcinoma, NAFLD, and NASH (22, 23). Here, the 
expressions of both CB receptors were evaluated using immunofluorescence (Figure 6A), which 
have revealed no or minimal expression of both receptors in the control groups. On the contrary, 
the MCD diet-fed groups showed an increase in the gene expression of both CB1 and CB2 
(Figure 6B and 6C). Although the CB2 receptor had higher expression, interestingly, when 
subjects were treated with the low dose of CBG, there was a significant decrease in the gene 
expression of both the CB1 (p<0.0001) and CB2 receptors (p<0.01) when compared to the MCD 
group.. Further, there was a general trend of co-localization of CB1 and CB2 receptors (shown as 
white dots).  Overall low dose CBG treatment seems reduced the expression of both CB1 and 
CB2 while high dosage of CBG did not change CB1 and CB2 expression induced by MCD; 
Meanwhile, the CBG treatment only is not enough to induce expression of  CB1 or CB2.  Yet, 
more investigations are still needed to obtain a better understanding of their roles in the liver, and 
more specifically, in the NASH progression.  
These observations lead us to investigate whether the CB receptors expression was 
enriched in immune cells that induced by the MCD diet. Thus, a co-staining against CB1, CB2, 
FcεRI was employed. FcεRI is a cell-surface receptor for the immunoglobulin IgE and is known 
to be the start point of a cascade of responses (57) such as the regulation and activation of mast 
cells (58). Recently, it was noticed that mast cells are found to be highly expressed during liver 




and FcεRI by the increase of gene expression in the MCD-fed groups. Interestingly, we noticed 
that both CB1 and CB2 are expressed in Mast cells (FcεRI+). No other cell types showed either 
CB1 or CB2 positive staining. This indicating the Mast cells might be activated by MCD-diet in 
mice liver via activation of both CB1 and CB2 receptors; while low CBG treatment inhibit the 
infiltration or activation of Mast cells in MCD group via decreased expression of CB1 and CB2. 
It is worth to notice that the expression of CB1 and CB2 expression decreased in MCD H. CBG 
group as well, while the Mast cell number seems not decreased, which might indicate the high 
CBG treatment might cause the Mast cell activation via a CB1 and CB2 independent pathway. 






Figure 6. Evaluation of CB receptors in liver frozen sections. 
Immunofluorescence staining of frozen liver sections for cannabinoid receptors 
1 and 2 (A, 20X), illustrating CB1 in green and CB2 in red. All images were 




   
Figure 7. Evaluation of CB receptors with FcεRI co-localization in liver frozen sections. 







SUMMARY AND CONCLUSIONS 
NASH is one of the most common liver diseases globally and is becoming a worldwide 
concern as cases continues to rise (9). The fact that there are no FDA-approved treatments for 
NASH makes the rise in cases more concerning. NASH patients are left with no treatment 
options and require liver transplants in most cases (9) as the disease keeps progressing to liver 
cirrhosis and/ or hepatocellular carcinoma. Pathologic features of NASH such as hepatic 
steatosis, fibrosis and inflammation are interconnected. This means that these pathologic features 
influence each other via positive feedback (38, 39).  The current study has used MCD diet to 
induce NASH in three weeks and has confirmed the development of NASH by the increase 
levels of steatosis levels, CD36 expression, fibrosis, and inflammation levels. Furthermore, this 
study has shown the therapeutic potential of CBG, as it reduced NASH-related pathologic 
features when administrated in low dose. 
Various studies have used other forms of cannabis such as CBD as a treatment for 
NAFLD (19, 40), but the effect of CBG in alleviating NASH has not been previously 
investigated. Interestingly, there was a positive correlation between the liver weight and the body 
weight when MCD-fed subjects were treated with a low dose of CBG, suggesting a trend in liver 
weight recovery. This trend could be explained by the fact that there is less fibrotic tissues and 
pro-inflammatory cytokines in the liver. Thus, this was an initial indication of the potential 
positive therapeutic effect of CBG in the liver. Yet, more investigations are still needed to 




However, we did not find significant differences in ALT levels (data not shown), which 
is consistent with other findings (8, 13, 14). Nevertheless, the ALT levels we measured might not 
be precise due to the increase levels hemolysis, which is a contributor to the levels of ALT in the 
mice serum. The increase levels of hemolysis were due to the improper blood collection, which 
lead to skewed ALT levels (60-62) Further measurements are still needed to confirm the effect of 
CBG on ALT levels. Likewise, we did not find significant changes on steatosis and involved 
biomarker CD36 gene expression in male mice. Taken together, we found CBG plays minimal 
role in altering the ALT levels as well as the steatosis in NASH ice model. The recovery trend 
and the positive correlation observed between the liver and body weight in the MCD L. CBG 
group could be due to another factor.  
This study is consistent with other studies that have used CBD, where they did not 
observe a statistical difference in the ALT levels using low dose of CBD (40). Another study by 
Wang Y. et al., found that 5mg/kg of CBD reduced hepatic steatosis in alcoholic fatty liver 
disease (19). Whereas our study did not observe any difference in hepatic steatosis with either 
the low dose (2.46 mg/kg) nor the high dose (24.6 mg/kg) of CBG in male mice. These findings 
were consistent with another study that used 0.05 mg/kg of Abn-CBD (atypical form of CBD) to 
treat NAFLD (40). Further, there was not any change in the import of fatty acids to the liver in 
any of the MCD-fed groups; indicating that CBG did not reduce the steatosis in the liver. Hence, 
this suggests that the recovery trend and the positive correlation observed between the liver and 
body weight in the MCD L. CBG group could be due to another factor.  
This study showed that liver fibrosis was induced as a result of the MCD diet and was 
alleviated with the administration of a low dose of CBG. However, the high dose of CBG also 




by the Pico-Sirius Red staining and α-SMA protein and mRNA expression decreased with the 
use of low dose CBG, but did not with high dose of CBG, which is consistent with other studies 
that have investigated liver fibrosis using low dose (0.05 mg/kg) of atypical CBD (40). Although 
these studies did not use similar doses, they have shown the potential of cannabis in reducing 
liver fibrosis when used in low amounts such as the dose used in this study. Despite the fact that 
low dose of CBG reduced fibrosis in the liver tissues, it is still important to acknowledge the fact 
that high dose of CBG have opposite effect. This is critical to take into consideration when 
administering CBG in future studies.  
Hepatic inflammation is one of the pathologic phenomena of NASH that could lead to 
liver dysfunction in NASH patients. A previous study has reported that hepatic inflammation 
plays an important role in the progression of hepatic steatosis and fibrosis (41). In this study, it 
was found that a low dose of CBG reduced the inflammation induced by the MCD diet, which 
was initially assessed using immunofluorescence staining for two of the white blood cells 
biomarkers, CD45 and F4/80, in frozen liver sections. The findings suggest that the low dose of 
CBG reduced infiltration of white blood cells in MCD diet-induced mice, while the high dose of 
CBG resulted in enhanced infiltration of white blood cells. Likewise, mRNA expression of 
NASH inflammation biomarkers, F4/80, was alleviated with intervention of low dose of CBG, 
but not TGFβ1 and IL-6. These findings are consistent with previous study showing an anti-
inflammatory effect of CBG (33). Similarly, other reports that found that F4/80 expression was 
reduced with the intervention of atypical CBD, yet they found reduction in IL-6 mRNA 
expression which is not consistent with the findings in this study (40). Overall, the findings 




The endocannabinoid systems involving CB 1 and CB 2, where CB1 receptor is primarily 
expressed in the brain and as well as other peripheral tissues (42).  In the brain, CB1 receptor 
controls appetite (24), but its antagonist showed evidence suggesting the ability to reduce obesity 
due to the fact that it reduces the food intake in rodents (43). On the other hand, the CB2 receptor 
is primarily expressed in the immune system. This study has found that the expression of CB1 
and CB2 receptors showed similar pattern to the inflammatory response in Figure 7, which lead 
us to investigate which cell is expressing these receptors. Our findings, indeed, confirmed that 
increased infiltration of Mast cells into the liver by MCD diet accompanied with enhanced CB 
receptors, while low dose CBG treatment reduced this trend. However, more mechanistic 
investigations are still needed to better understand the observed results. 
In summary, this study observed the protective effect of CBG in MCD diet-induced 
NASH in mice. A low dose of CBG reduced hepatic fibrosis and hepatic inflammation but not 
hepatic steatosis while a high dose of CBG worsened the pathologic features of NASH. In 
conclusion, this study provides initial findings and a foundation for future studies on the efficacy 
of CBG on NASH.  
Limitations 
This thesis investigated the role of CBG in alleviating the pathologic features associated 
NASH such as steatosis, fibrosis and inflammation in C57BL/6 male mouse model, and there 
were several important limitations.  
First, the MCD diet is known to induce NASH in a short period of time, yet it does not 
replicate metabolic syndrome seen in human NASH patients. In fact, the MCD diet shows 
reversed metabolic syndrome etiology in rodent models. However, since this study’s main 




appropriate. Additionally, this diet is considered the most accessible and affordable diet for the 
purpose of this study.  
Further, the reversibility of the NASH with the administration of different doses of CBG 
was not answered in this study due to the lack of mice availability. This could be measured in the 
future by measuring the levels of steatosis, fibrosis, and inflammation in the liver prior to the 
administration of CBG. Once the course of CBG have finished, the reversibility could be 
assessed by comparing the liver morphologies before and after the intervention of CBG.  
Although, biological sex of the mice was taken into consideration during the 
experimental design; only male C57BL/6 mice were used. Although the biological sex factor 
would be of interest, due to the time restriction as we only had 3 months to treat the mice and 
collect tissues, only C57BL/6 male mice were used for evaluating the role of CBG in alleviating 
the pathologic features associated with NASH, since male C57BL/6 mice show NASH 
symptoms more that the female ones (56). 
Lastly, there were only 6 mice in each group in this experiment which is considered a 
relatively small sample size. The small sample size could explain the lack of significance 
detected between some groups which is due to the low power of detecting statistical difference as 
well as to the increase in the variation between group. In this thesis, small sample sizes (n=36) 
were used due to time and financial resources restraints. 
Future Directions 
While this study demonstrated the potential in using CBG as a therapeutic agent in MCD 
diet-induced NASH in C57BL/6 male mice, further rigorous study is needed to confirm the 




 In order to determine the potential use of CBG as a treatment for NASH, further 
understanding of oxidative stress and cellular senescence is needed. Oxidative stress is defined as 
the imbalance of free radicals and antioxidant particles in the body (44). It was suggested to 
likely be the start point of the damage in the liver caused by the high fat diet (45). Cellular 
senescence is defined as the cell cycle arrest that is combined with proinflammatory cytokine 
secretion. Further, hepatic cellular senescence was shown to be correlated with fat accumulation 
and the progress of NAFLD to NASH (46). Investigating oxidative stress and cellular senescence 
pathways could aid in understanding the progression of the disease in both human and non-
human models.  
Even though our study has showed promising change in expression of both the CB1 and 
CB2 receptors with the use of a low dose of CBG in MCD-fed mice, the endocannabinoid 
system is a possible area of investigation. As previously mentioned, the CB1 receptor is mainly 
expressed in the central nervous system while being expressed in lower levels in various 
peripheral tissues. A previous study showed that blocking the CB1 receptor reduced liver fibrosis 
in mouse models though the CB1 receptor/β‐arrestin1/Akt pathway (47). This indicates that the 
CB1 receptor plays a role in the progression of NASH, meaning that it is important to understand 
the impact of CBG on CB1 receptor-involved pathways.  
Further, the long-term impact of CBG on the liver and on the progression of NASH have 
not yet been investigated. Generally, the lack of long-term effect of any treatment leads to the 
treatment being considered controversial and uncertainty in the effectiveness of the proposed 
treatment is likely to arise. This study administrated CBG to NASH mouse models for only two 
weeks, but it has did not investigate the impact of using CBG for longer than two week, and 




seen with low dose of CBG. Therefore, it is vital to understand the long-term impact and safety 
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Treatment with the chemotherapy drug doxorubicin (DOX) may lead to toxicities that 
affect non-cancer cells including the liver. Supplementing the diet with creatine (Cr) has been 
suggested as a potential intervention to minimize DOX-induced side effects, but its effect in 
alleviating DOX-induced hepatoxicity is currently unknown. Therefore, we aimed to examine 
the effects of Cr supplementation on DOX-induced liver damage. Male Sprague-Dawley rats 
were fed a diet supplemented with 2% Cr for four weeks, 4% Cr for one week followed by 2% 
Cr for three more weeks, or control diet for four weeks. Animals then received either a bolus i.p. 
injection of DOX (15 mg/kg) or saline as a placebo. Animals were then sacrificed five days-post 
injection and markers of hepatoxicity were analyzed using the liver-to-body weight ratio, 
aspartate transaminase (AST)-to- alanine aminotransferase (ALT) ratio, alkaline phosphatase 
(ALP), lipemia, and T-Bilirubin. In addition, hematoxylin and eosin (H&E) staining, Picro-Sirius 
Red staining, and immunofluorescence staining for CD45, 8-OHdG, and β-galactosidase were 
performed to evaluate liver morphology, fibrosis, inflammation, oxidative stress, and cellular 
senescence, respectively. The mRNA levels for biomarkers of liver fibrosis, inflammation, 
oxidative stress, and senescence-related genes were measured in liver tissues. Chromosomal 
stability was evaluated using global DNA methylation ELISA. The ALT/AST ratio and liver to 




attenuate this increase. Furthermore, elevated levels of liver fibrosis, inflammation, oxidative 
stress, and senescence were observed with DOX treatment, and Cr supplementation prior to 
DOX treatment ameliorated this hepatoxicity. Moreover, DOX treatment resulted in 
chromosomal instability (i.e., altered DNA methylation profile), and Cr supplementation showed 
a tendency to restore chromosomal stability with DOX treatment. The data suggest that Cr 
protected against DOX-induced hepatotoxicity by attenuating fibrosis, inflammation, oxidative 
stress, and senescence. 
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